Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sci Adv. 2022 Jun 17;8(24):eabo4271. doi: 10.1126/sciadv.abo4271. Epub 2022 Jun 15.
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD, is up-regulated in CD8 T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8 T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8 T cell-targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.
感染是系统性红斑狼疮(SLE)患者死亡的主要原因之一。我们之前发现,CD38 是一种调节 NAD 产生的细胞外酶,在 SLE 患者的 CD8 T 细胞中上调,并与感染风险相关。在这里,我们报告称,CD38 通过抑制线粒体自噬的多个步骤来降低 CD8 T 细胞的功能,而线粒体自噬对于线粒体质量控制至关重要。使用一种狼疮小鼠模型,我们发现,以 CD8 T 细胞为靶点的 CD38 抑制剂的给药能够恢复其效应功能,逆转自噬和线粒体缺陷,并改善病毒清除。我们得出结论,CD38 是降低 SLE 患者感染率的一个靶点。